Did Harmony Biosciences Holdings, Inc. Mislead Investors Shareholder Rights Advocates at Levi Korsinsky Investigate- HRMY
| HRMY Stock | USD 33.47 3.50 9.47% |
Slightly above 60% of Harmony Biosciences' investor base is looking to short. The analysis of overall sentiment of trading Harmony Biosciences Holdings stock suggests that many investors are alarmed at this time. Harmony Biosciences' investing sentiment can be driven by a variety of factors including economic data, Harmony Biosciences' earnings reports, geopolitical events, and overall market trends.
Harmony |
NEW YORK, NY ACCESSWIRE November 5, 2024 Levi Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc.
Read at accesswire.com
 |
Harmony Biosciences Fundamental Analysis
We analyze Harmony Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Harmony Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Harmony Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Harmony Biosciences is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Harmony Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Harmony Biosciences stock to make a market-neutral strategy. Peer analysis of Harmony Biosciences could also be used in its relative valuation, which is a method of valuing Harmony Biosciences by comparing valuation metrics with similar companies.
Peers
Harmony Biosciences Related Equities
| PTGX | Protagonist Therapeutics | 3.02 | ||||
| SNDX | Syndax Pharmaceuticals | 2.17 | ||||
| TVTX | Travere Therapeutics | 1.84 | ||||
| VRNA | Verona Pharma | 1.81 | ||||
| INZY | Inozyme Pharma | 1.68 | ||||
| NUVL | Nuvalent | 1.52 | ||||
| VTYX | Ventyx Biosciences | 0.66 | ||||
| FENC | Fennec Pharmaceuticals | 0.45 | ||||
| EWTX | Edgewise Therapeutics | 0.28 | ||||
| KROS | Keros Therapeutics | 0.27 | ||||
| VRDN | Viridian Therapeutics | 0.06 | ||||
| JANX | Janux Therapeutics | 0.28 | ||||
| IDYA | Ideaya Biosciences | 0.48 | ||||
| REPL | Replimune | 0.88 | ||||
| NVCT | Nuvectis Pharma | 1.01 | ||||
| PLRX | Pliant Therapeutics | 1.58 | ||||
| KRON | Kronos Bio | 2.00 | ||||
| RVMD | Revolution Medicines | 2.03 | ||||
| GOSS | Gossamer Bio | 3.08 | ||||
| LYRA | Lyra Therapeutics | 4.76 | ||||
| GPCR | Structure Therapeutics | 5.74 |
Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.